乾癬性関節炎患者における3年間のウステキヌマブまたはTNF阻害薬の患者報告アウトカムと労働生産性の改善: PsABio 実臨床結果
Arthritis Res Ther. 2023 Jun 23;25(1):109. doi: 10.1186/s13075-023-03058-y
Results from the 3-year PsABio study demonstrated that, generally, ustekinumab and TNFi treatment led to an improvement in PROs. In coming to this conclusion, researchers aimed to evaluate the real-world effect of ustekinumab or a TNFi on PRO and their association with effectiveness endpoints in PsA patients over 3 years.
In certain PROs, TNFi-treated patients showed a greater improvement compared with ustekinumab-treated patients. Patients achieving effectiveness endpoints had improved PROs, independent of treatment group. These findings may be useful for physicians in aiding treatment decisions in clinical practice.
Keywords:
